Clinical Trials Logo

Lymphoproliferative Disorders clinical trials

View clinical trials related to Lymphoproliferative Disorders.

Filter by:

NCT ID: NCT00176826 Terminated - Clinical trials for Hematologic Diseases

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Start date: September 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.

NCT ID: NCT00176475 Terminated - Lymphoma Clinical Trials

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Start date: January 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving irradiated donor lymphocytes together with rituximab may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving irradiated donor lymphocytes together with rituximab works in treating patients with relapsed or refractory lymphoproliferative disease.

NCT ID: NCT00123942 Terminated - Clinical trials for Lymphoproliferative Disorders

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Start date: April 2004
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.

NCT ID: NCT00093704 Terminated - Lymphoma Clinical Trials

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Start date: March 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Giving ganciclovir together with bortezomib may kill more Epstein Barr virus-infected cancer cells. PURPOSE: This clinical trial is studying how well giving bortezomib together with ganciclovir works in treating patients with relapsed or refractory Epstein Barr virus-positive lymphoma.

NCT ID: NCT00087009 Terminated - Lymphoma Clinical Trials

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Start date: May 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Beta-glucan may increase the effectiveness of rituximab by making cancer cells more sensitive to the monoclonal antibody. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when given together with rituximab in treating young patients with relapsed or progressive lymphoma or leukemia or with lymphoproliferative disorder related to donor stem cell transplantation.

NCT ID: NCT00036855 Terminated - Clinical trials for Post-transplant Lymphoproliferative Disorder

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Start date: June 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver radioactive tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by anticancer therapy

NCT ID: NCT00006054 Terminated - Clinical trials for Graft Versus Host Disease

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Start date: March 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II. Determine relevant outcomes of this treatment in these patients including quality of survival, extent of morbidity and mortality from complications of the treatment (e.g., graft versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and completeness of functional immunoreconstitution.